In8bio Inc Cash Flow Conversion Efficiency
In8bio Inc cash flow conversion efficiency. Based on the latest financial reports, In8bio Inc (INAB) has a cash flow conversion efficiency ratio of -0.204x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.75 Million) by net assets ($18.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of In8bio Inc (2018–2025)
Cash flow conversion efficiency of In8bio Inc from 2018 to 2025. This chart illustrates how In8bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View INAB stock price for real-time trading data and today's change.
In8bio Inc Cash Flow Conversion Ratio Explained
In8bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
In8bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of In8bio Inc ranked by their cash flow conversion efficiency. Also see INAB market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bolt Biotherapeutics
NASDAQ:BOLT
|
-0.270x |
|
PowerBank Corporation
NEO:PBK
|
0.079x |
|
Pharmena S.A.
WAR:PHR
|
-0.078x |
|
North Arrow Minerals Inc
V:NAR
|
-0.011x |
|
Kesla Oyj A
HE:KELAS
|
0.068x |
|
Asmallworld AG
SW:ASWN
|
0.480x |
|
Locate Technologies Ltd
AU:LOC
|
-0.104x |
|
Pergamon Status Dis Ticaret AS
IS:PSDTC
|
-0.002x |
Annual Cash Flow Conversion Efficiency for In8bio Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of In8bio Inc from 2018 to 2025. Review how financially flexible is In8bio Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.56 Million | $-12.71 Million | -0.461x | +72.34% |
| 2024-12-31 | $14.48 Million | $-24.15 Million | -1.668x | -78.21% |
| 2023-12-31 | $24.94 Million | $-23.34 Million | -0.936x | +11.79% |
| 2022-12-31 | $22.73 Million | $-24.12 Million | -1.061x | -199.92% |
| 2021-12-31 | $38.18 Million | $-13.51 Million | -0.354x | +9.13% |
| 2020-12-31 | $18.32 Million | $-7.13 Million | -0.389x | -102.81% |
| 2019-12-31 | $-346.00K | $-4.80 Million | 13.876x | +2428.66% |
| 2018-12-31 | $4.65 Million | $-2.77 Million | -0.596x | -- |
About In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell… Read more